MedPath

A comparison of 150mg and 75mg aspirin for preventing preterm preeclampsia and associated fetal growth restriction amongst women at risk in Abuja: a randomised controlled study

Not Applicable
Not yet recruiting
Conditions
Pregnancy and Childbirth
Registration Number
PACTR202312795734215
Lead Sponsor
Dr. Suraiya Auwal Suleiman
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Female
Target Recruitment
95
Inclusion Criteria

iPresence of one high risk factor for preeclampsia: Previous history of hypertensive disorders of pregnancy, autoimmune diseases (SLE and APS), chronic hypertension, diabetes mellitus.
iiPresence of two or more moderate risk factors for preeclampsia: =35 years, first pregnancy, nulliparity, BMI =30kg/m2, pregnancy interval >10 years, family history of preeclampsia, personal history (low birth weight or small for gestational age, and previous adverse pregnancy outcome).
iiiWillingness to be followed up until 37 weeks or occurrence of outcome.

Exclusion Criteria

iHypersensitivity to aspirin
iiLong-term use of non-steroidal anti-inflammatory drugs (NSAID)
iiiAsthmatic patients
ivChronic liver or kidney disease
vBleeding disorders including peptic ulcer disease
viCigarette smoking, alcohol consumption or illicit drug use
viiMultifetal gestation
viiiFetal congenital anomalies

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.